BLRX 6-K: Divestiture

BioLineRx

Filed with the SEC on · accession 0001178913-26-005266

BLRX filed a 6-K (foreign company report) with the SEC on Nov 18, 2026. BioLineRx entered into a Purchase and Sale Agreement with SCOF Motixafortide Holdings, Inc., an affiliate of Soleus Capital Management, to sell 80% of its future royalty payments on net sales of APHEXDA (motixafortide) under its license agreement with Ayrmid Pharma for a one-time purchase price of…

Summary of the filing

BioLineRx entered into a Purchase and Sale Agreement with SCOF Motixafortide Holdings, Inc., an affiliate of Soleus Capital Management, to sell 80% of its future royalty payments on net sales of APHEXDA (motixafortide) under its license agreement with Ayrmid Pharma for a one-time purchase price of $5.6 million. The company will retain 20% of the royalties and use proceeds to support R&D, including GLIX1 clinical development, and to partially prepay $3.0 million of its loan with Kreos Capital.

Key details

One-time purchase price for 80% of future royalty payments$5.6M
Purchaser's documented reasonable transaction expenses cap$100K
Partial loan prepayment to Kreos Capital at closing$3.0M
Remaining outstanding amount under Loan Agreement after prepayment$2.0M
Financial advisory fee to Chardan Capital Markets$400K
Minimum cash balance covenant under Loan Agreement to be eliminated$4.0M
Registrant, seller of royalty interestBioLineRx Ltd.
Purchaser, affiliate of soleus capital management, l.p.SCOF Motixafortide Holdings, Inc.
Affiliate of the purchaserSoleus Capital Management, L.P.
Licensee under the ayrmid license, obligated to pay royalties on aphexda net salesAyrmid Pharma Ltd.
Original licensor of motixafortide to biolinerx, entitled to a portion of retained royaltiesBiokine Therapeutics Ltd.
Lender under loan agreement, affiliate of blackrock, consented to transaction and released security interestKreos Capital VII Aggregator SCSp
Financial advisor to biolinerx, will receive approximately $0.4 million feeChardan Capital Markets, LLC
Chief executive officerPhilip A. Serlin

✦ Ask GOAX AI about this filing — what it means for BLRX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for BLRX?

Click here

Frequently asked questions

What did BLRX file with the SEC on Nov 18, 2026?

BLRX filed a 6-K (Divestiture). BioLineRx entered into a Purchase and Sale Agreement with SCOF Motixafortide Holdings, Inc., an affiliate of Soleus Capital Management, to sell 80% of its future royalty payments on net sales of APHEXDA (motixafortide) under its license agreement with Ayrmid Pharma for a one-time purchase price of $5.6 million. The company will retain 20% of the royalties and use proceeds to support R&D, including GLIX1 clinical development, and to partially prepay $3.0 million of its loan with Kreos Capital.

What does a divestiture mean for BLRX stock?

A contract important enough that investors need to know about it — a big customer contract, a loan, a merger agreement or a partnership.

How do I read a 6-K?

How foreign companies listed in the US report news and events — like an 8-K for them. Look at the exhibit names: "results", "resign", "notice" tell you the topic. Many 6-Ks are routine (meeting notices); results and leadership changes matter most.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 6-K (foreign company report): How foreign companies listed in the US report news and events — like an 8-K for them.

Other BLRX SEC filings

Get alerts when BLRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days